Holen Sie sich die Stockscreener-App
23.17
0.30%
0.07
Handel nachbörslich:
23.28
0.11
+0.47%
Schlusskurs vom Vortag:
$23.10
Offen:
$23.46
24-Stunden-Volumen:
970.74K
Relative Volume:
0.83
Marktkapitalisierung:
$1.75B
Einnahmen:
$122.87M
Nettoeinkommen (Verlust:
$-73.68M
KGV:
-23.64
EPS:
-0.9803
Netto-Cashflow:
$-39.27M
1W Leistung:
-12.96%
1M Leistung:
-10.21%
6M Leistung:
+70.74%
1J Leistung:
+63.98%
1-Tages-Spanne:
$22.80
$23.81
1-Wochen-Bereich:
$22.80
$27.13
52-Wochen-Spanne:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
23.17 | 1.74B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
Aug Macro: Is Zymeworks Inc. stock vulnerable to regulatory risksQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
Can Zymeworks Inc. stock hit analyst price targetsWeekly Volume Report & Weekly Top Performers Watchlists - ulpravda.ru
Earnings Beat: How Zymeworks Inc stock reacts to oil pricesJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - moha.gov.vn
How Zymeworks Inc. stock reacts to oil pricesShare Buyback & Weekly Stock Performance Updates - ulpravda.ru
Zymeworks (ZYME) Is Down 5.6% After Positive Phase 3 Ziihera Data Unlocks US$440 Million Milestones - simplywall.st
Will Zymeworks Inc. stock benefit from upcoming earnings reportsTrend Following Strategies & Affordable Trading Plans - ulpravda.ru
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial - Benzinga
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial - Sahm
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial - TipRanks
Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera as Potential New Standard of Care in HER2-Positive First-Line Metastatic GEA - Quiver Quantitative
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewswire
Redlands Daily Facts - FinancialContent
Paul Andrew Moore Sells 20,110 Shares of Zymeworks (NYSE:ZYME) Stock - MarketBeat
Jeffrey Smith Sells 10,538 Shares of Zymeworks (NYSE:ZYME) Stock - MarketBeat
Insider Selling: Zymeworks (NYSE:ZYME) CEO Sells 54,343 Shares of Stock - MarketBeat
Zymeworks (NASDAQ:ZYME) Stock Price Down 6.8%What's Next? - MarketBeat
Zymeworks (NYSE:ZYME) Stock Price Down 6.1%Should You Sell? - MarketBeat
Zymeworks (ZYME): Biotech under pressure as investors wait for the next catalyst - AD HOC NEWS
Zymeworks Inc: Can ZYME’s Quiet Rally Turn Into a Breakout Story? - AD HOC NEWS
Zymeworks shareholders back directors, executive pay and auditor - MSN
Zymeworks shareholders elect directors and approve compensation at annual meeting - Investing.com
Zymeworks Shareholders Back Directors, Executive Pay and Auditor - TipRanks
Short Interest in Zymeworks Inc. (NASDAQ:ZYME) Drops By 29.8% - MarketBeat
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adeno - Macau Business
Zymeworks Announces Participation in Upcoming Investor Conferences - Macau Business
Kenneth Galbraith Sells 47,528 Shares of Zymeworks (NYSE:ZYME) Stock - MarketBeat
Zymeworks Insider Sold Shares Worth $1,284,311, According to a Recent SEC Filing - marketscreener.com
Is Zymeworks Inc. stock vulnerable to regulatory risksBull Run & Daily Chart Pattern Signal Reports - Улправда
How rising interest rates impact Zymeworks Inc. stockIndex Update & AI Based Buy/Sell Signal Reports - ulpravda.ru
Zymeworks Inc. $ZYME Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Aug Fed Impact: How rising interest rates impact Zymeworks Inc. stockTrade Entry Report & Expert-Curated Trade Recommendations - Улправда
Why retail investors pile into Zymeworks Inc. stock2025 Winners & Losers & Low Drawdown Investment Strategies - DonanımHaber
Is Zymeworks Inc. (NASDAQ:ZYME) Trading At A 50% Discount? - Yahoo Finance
Zymeworks Inc. $ZYME Shares Acquired by Squarepoint Ops LLC - MarketBeat
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Buy" from Analysts - MarketBeat
How institutional buying supports Zymeworks Inc. stockPortfolio Gains Report & Community Verified Swing Trade Signals - ulpravda.ru
Free cash flow per share of Zymeworks Inc. – TRADEGATE:ZA8 - TradingView — Track All Markets
Buy Signal: How rising interest rates impact Zymeworks Inc. stockMarket Activity Recap & Trade Opportunity Analysis - Улправда
Will Zymeworks Inc. (ZA8) stock return to pre crash levelsJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
Truist Initiates Zymeworks at Buy With $40 Price Target - marketscreener.com
Zymeworks (NYSE:ZYME) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Zymeworks (NASDAQ:ZYME) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat
Zymeworks (NYSE:ZYME) Shares Gap UpWhat's Next? - MarketBeat
Zymeworks (NASDAQ:ZYME) Shares Gap UpHere's What Happened - MarketBeat
EcoR1 Capital LLC Increases Stake in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Wells Fargo Upgrades Zymeworks (ZYME) - Nasdaq
Zymeworks (ZYME) Receives Rating Upgrade and Increased Price Tar - GuruFocus
Redmile Group LLC Sells 638,318 Shares of Zymeworks Inc. $ZYME - MarketBeat
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):